心力衰竭是一个全球性问题,目前全世界有3800万患者,且随着人口老龄化,这个数字会逐渐增加.基因治疗是将目的基因导入靶细胞,转移并表达特异的基因,从而改善失去正常功能的蛋白质,或是抑制不利基因的表达,根据心力衰竭时神经内分泌、细胞因子的改变,考虑不同的病因,导入不同的基因,达到治疗心力衰竭的目的.心力衰竭基因治疗至今已开展近30年,存在某些靶点研究被淹没的同时,已有部分基因治疗的研究开展至临床试验,以下对心力衰竭基因治疗的最新研究进展做一综述.%Heart failure is a global problem and it is currently estimated at 38 million patients worldwide,with an increasing population aging.Gene therapy is the purpose of the target gene into target cells,transfer and expression of specific genes,thereby improving the loss of normal function of the protein,or inhibition of adverse gene expression,according to heart failure neuroendocrine,cytokines change,consider different causes,import different genes,to achieve the purpose of treatment of heart failure.Gene therapy of heart failure has been carried out for nearly 30 years,some of the target study has been declining,and some gene therapy research has been carried out to clinical trials.The following review is the latest research progress in gene therapy of heart failure.
展开▼
